ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Engineered Carbon Dots from a Traditional Herb Pair Orchestrate Concurrent Antioxidant and AP-1-Mediated Inflammation to Attenuate Renal Ischemia-Reperfusion Injury.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Renal ischemia-reperfusion (I/R) injury, a primary cause of acute kidney injury (AKI), is driven by a self-amplifying loop of oxidative burst and immune cell infiltration. In this work, the classical herb pair Astragalus membranaceus (AM) and Angelica sinensis (AS) is employed as a composite precursor to synthesize nitrogen-rich carbon-dot nanozymes (AM-AS@CDs) via a one-step hydrothermal method. AM‑AS@CDs exhibit superoxide dismutase (SOD)-mimetic activity superior to that of CDs derived from single herbs. In vitro, AM-AS@CDs effectively alleviate oxidative stress-induced cellular damage and significantly inhibit apoptosis. In vivo, AM-AS@CDs markedly attenuate I/R-induced AKI and reduce immune cell infiltration in renal tissues. Transcriptomic analyses reveal that AM-AS@CDs downregulate the expression and phosphorylation of Fosl1 and c-Jun. Consequently, the AP-1-chemokine signaling axis is disrupted, which reduces immune cell recruitment. Furthermore, AM-AS@CDs restore redox homeostasis by upregulating antioxidant enzymes such as SOD, glutathione peroxidase 4 (GPX4), and catalase (CAT). They also attenuate the excessive activation of the Nrf2/HO-1 pathway. Overall, this precursor-formulation strategy enables precise modulation of heteroatom doping and surface chemistry in CDs. AM-AS@CDs effectively interrupt the oxidative-inflammatory positive feedback loop through dual mechanisms. These findings provide both theoretical and material foundations for the development of natural product-based nanozymes for I/R-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.